Related by context. All words. (Click for frequent words.) 78 Medical Oncology ESMO 77 Respiratory Society 76 EULAR Annual 76 EULAR 73 Diabetes EASD 73 Rheumatology EULAR 72 Liver EASL 72 Cardiology ESC 71 ECTRIMS 71 ERA EDTA 70 ECCO ESMO 70 ISPOR 70 UEGW 69 Urology EAU 69 Venereology EADV 68 Infectious Diseases ECCMID 68 ESMO 68 Digestive Disease Week DDW 68 Radiology ECR 68 Association EHA 67 Clinical Microbiology 67 Hypertension ESH 66 Venereology 66 Society CTOS 65 Digestive Disease Week 65 Gastrointestinal Cancer 65 nd Annual Meeting 65 Cardiostim 65 Genitourinary Cancers Symposium 65 Multiple Sclerosis ECTRIMS 65 Gastrointestinal Cancers Symposium 65 Allergology 65 ASCO GI 65 AACR San Antonio 65 Gynecologic Cancer Society 64 EFNS 64 Clinical Oncology Annual Meeting 64 EuroPCR 64 OARSI 64 European CanCer Organisation ECCO 64 ECCMID 64 International OARSI 64 ASH Annual Meeting 64 Cardiology Heart Failure 64 Haemostasis ISTH 64 Annual Scientific Sessions 63 Neurological Societies 63 Cancers Symposium 63 Rheumatology 63 Connective Tissue Oncology 63 Hematology ASH 63 st Annual Meeting 63 Hematology Meeting 63 ECNP 63 Arteriosclerosis Thrombosis 63 Vascular Biology ATVB 63 ICAAC IDSA 63 Therapeutics TCT scientific 62 AACR #st Annual Meeting 62 Endocrine Society #st 62 Transcatheter Cardiovascular Therapeutics 62 AHA Scientific Sessions 62 AUA Annual Meeting 62 EADV 62 EASD 62 Oncology ESTRO 62 Hematology ASH Annual Meeting 62 Therapeutics TCT 62 Pharmacoeconomics 62 #th Annual Interscience 62 EASL 62 AASLD 62 Cardiology ESC Congress 62 Retina Specialists 62 Chemotherapy ICAAC 62 Hematology Annual Meeting 62 #st Annual Meeting 62 Neuropsychopharmacology 62 Clinical Oncology ASCO Annual 61 Transcatheter Cardiovascular Therapeutics TCT 61 Late Breaker 61 ASCO Annual Meeting 61 EORTC NCI AACR 61 AACR NCI EORTC 61 Malignant Lymphoma 61 CTRC AACR San Antonio 61 PROactive Study 61 Opportunistic Infections CROI 61 America HFSA 61 Percutaneous Cardiovascular Interventions 61 Cardiac Techniques 61 SABCS 61 EACTS 61 Scientific Session 61 International Myeloma Workshop 61 Immunology Annual Meeting 60 RoACTEMRA 60 Scientific Meeting 60 EUROGIN 60 Rheumatology Annual 60 Therapeutic Radiology 60 TG MV 60 Neurological Societies EFNS 60 Interventional Radiological Society 60 Rheumatology ACR Annual 60 Scientific Sessions 60 Digestive Diseases Week 60 ESCRS 60 Outcomes Research ISPOR 60 Breast Cancer Symposium SABCS 60 Clinical Oncology ASCO 60 Antimicrobial Agents 60 Molecular Targets 59 Neurology AAN 59 Cimzia ® certolizumab pegol 59 EORTC NCI AACR Symposium 59 Related Disorders ICAD 59 EORTC 59 ICAAC 59 Neurological Surgeons CNS 59 ORAL Sync 59 Infectious Disease ECCMID 59 Clinical Immunology EAACI 59 Advanced Neuroendocrine Tumors 59 Symposium SABCS 59 ADA Scientific Sessions 59 Neck Surgery Foundation 59 Annual Transcatheter Cardiovascular 59 EAACI 59 Endourology 59 Endocrine Society ENDO 59 Nephrology Renal Week 59 #nd Annual Meeting 59 annual Transcatheter Cardiovascular 59 Hematology 58 AACR #nd Annual Meeting 58 EORTC NCI 58 Alzheimer Disease ICAD 58 tocilizumab 58 Neuropathic Pain 58 ASBMR 58 Clinical Oncology Gastrointestinal Cancers 58 Cancer iSBTc 58 Cardiology Scientific Sessions 58 ISTH 58 Heart Failure Society 58 sorafenib tablets 58 AAO HNSF Annual Meeting 58 ESTRO 58 #nd EORTC NCI 58 Lung Transplantation 58 USpella 58 Pharmaceutical Scientists AAPS 58 Diabetologia 58 Headache Society 58 American Thoracic Society 58 Hernia Society 57 AIR2 Trial 57 dose escalation clinical 57 Epileptology 57 Pediatric Academic Societies PAS 57 #rd Annual CTRC 57 Hypertension ASH 57 teriflunomide 57 Ranolazine 57 Gastroenterology Week UEGW 57 Systemic Sclerosis 57 RECORD1 57 GASTRO 57 Multicenter 57 Interventional Radiology SIR 57 Oligonucleotide Therapeutics Society 57 & Immunology AAAAI 57 Breast Cancer Symposium 57 Biological Therapy 57 ACR ARHP 57 Neurological Surgeons Annual Meeting 57 Endocrine Society #nd 57 Liver Diseases 57 Clinical Chemistry AACC 57 Refractive Surgeons ESCRS 57 ABCSG 57 Cardiovascular Anesthesiologists 57 ASCO Genitourinary Cancers Symposium 57 hyperphenylalaninemia HPA due 57 TORISEL TM 57 Chicago Multidisciplinary Symposium 57 Lysosomal Disease Network 57 Certican 57 Refractive Surgeons 57 Ophthalmic Drugs Advisory 57 ASGT 57 Oral Implantologists 57 INSPIRE Trial Phase III 56 Therapeutic Radiation 56 AVERROES 56 orally inhaled migraine 56 Romiplostim 56 Neuropsychopharmacology ECNP 56 Liver Diseases AASLD 56 pregabalin Lyrica 56 multicenter prospective 56 Continence Society 56 Pediatric Academic Societies 56 Hyperthermic Oncology ESHO 56 RIO Lipids 56 Breast Surgeons ASBS 56 TMC# C# 56 Neupro R 56 AAPS Annual Meeting 56 Rheumatology ACR 56 Hematology ASH Meeting 56 International Papillomavirus 56 CROI 56 Aryplase 56 Sorafenib HCC Assessment 56 Clinical Practice Guideline 56 #th Interscience Conference 56 ® DDW 56 Addex Pharmaceuticals SIX ADXN 56 Oral Fingolimod 56 Hexvix 56 EURIDIS 56 Paediatric Infectious Diseases 56 Solorel TM 56 orphan medicinal product 56 Kuvan sapropterin dihydrochloride 56 CTI Nasdaq 56 interferon gamma 1b 56 Selective Cardiac Myosin Activator 56 AACR symposium 56 II Clinical Trial 56 European CanCer Organisation 56 evaluating tivozanib 56 EFORT Congress 56 & OTO EXPO 56 CONBRIZA 56 Minimally Invasive Gynecology 56 AAN Annual Meeting 56 pulmonary arterial hypertension PAH 56 CIRSE 56 CombAT 56 Esbriet ® 56 oral FTY# 56 alvimopan 56 Cardiology 56 CLL8 56 DDW ® 56 Keppra ® levetiracetam 56 ARCOXIA 55 number NCT# ClinicalTrials.gov 55 Mineral Research ASBMR 55 Clinical Trial Results 55 Trandolapril 55 SmPC 55 BiTE R 55 Hsp# Inhibitor 55 Angiology 55 Female Urology 55 Multicenter Study 55 Selective Cardiac Myosin 55 Medical Oncology 55 Gastroenterology ACG 55 Randomized Study 55 Intervention Effectiveness 55 ongoing Phase 1b 55 Medicinal Products EMEA 55 Spine Arthroplasty Society 55 Sanofi aventis EURONEXT SAN 55 J Am Coll 55 Interventions SCAI 55 Embryology ESHRE 55 Combination REOLYSIN R 55 Phenoptin 55 Belimumab 55 Safinamide 55 Oncology ASTRO 55 Neoplasia 55 Cardiology ACC 55 Prostate Cancer Symposium 55 Phase III Clinical Trial 55 Cardiometabolic 55 Pharmacological Research 55 Deutsches Herzzentrum 55 Phase III placebo controlled 55 Prospective Multicenter 55 ISHLT 55 Poster Presentation 55 ELIQUIS 55 Experimental Biology EB 55 Intraoperative Surgical Planning 55 FOLFOX6 chemotherapy regimen 55 Intensive Care Medicine 55 Raptiva R 55 Clinical Efficacy 55 Prostate AdenoCarcinoma Treatment 55 Endocrine Society Annual Meeting 55 Vascular Annual Meeting 55 YONDELIS R 55 Pirfenidone 55 J Clin Oncol 55 Phase IIIb clinical 55 Onbrez Breezhaler 55 Brentuximab Vedotin SGN 55 lexidronam injection 55 COMFORT II 55 Spine Society 55 ASCO GU 55 Phacilitate Vaccine Forum 55 Neuro Oncology SNO 55 ExTRACT TIMI 55 Clinical Oncologists 54 ASCO Breast Cancer 54 evaluating REVLIMID 54 Fondaparinux 54 Diabetic Macular Edema 54 Interscience Conference 54 CARE HF 54 phase IIb study 54 Zenvia Phase III 54 PreCISe 54 bazedoxifene conjugated estrogens 54 Inflammatory Bowel Diseases 54 CIMZIA TM certolizumab pegol 54 Edge STudy 54 Urology EAU Congress 54 DIA EuroMeeting 54 AACR Frontiers 54 Afinitor ® 54 CLARITY study 54 ACTEMRA TM 54 Arterial Hypertension 54 CLARITY TIMI 54 arthritis PsA 54 Canaccord Adams Hepatitis C 54 HUPO 54 NO# [002] 54 phase IIIb 54 riociguat 54 ankylosing spondylitis AS 54 ACR ARHP Annual 54 Ovarian PLCO Cancer 54 Liver Disease AASLD 54 V Everolimus Eluting Coronary 54 placebo controlled Phase III 54 Neurological Surgeons 54 novel VDA molecule 54 Safety Tolerability 54 Neuroendocrinology 54 BARACLUDE R 54 Febuxostat 54 By JENNIFER LEARN 54 Femara letrozole 54 Cell Biology ASCB 54 ASCEND HF 54 American Psychosomatic Society 54 Retina Specialists ASRS 54 atherothrombotic events 54 Preclinical Data 54 registrational Phase 54 EXPAREL ™ 54 IL# PE#QQR 54 FOLOTYN ® 54 Cancer EORTC 54 multicentre study 54 CYPHER R Sirolimus eluting 54 PROSTVAC TM 54 Immunology ACAAI 54 Presents Positive 54 vapreotide acetate 54 Receives Marketing Authorization 54 diabetic neuropathic pain 54 Diabetes EASD Annual Meeting 54 AACR Meeting 54 Traficet EN 54 Abstract Accepted 54 sapropterin dihydrochloride 54 RANK Ligand inhibitor 54 Betaferon R 54 prucalopride 54 Amrubicin 54 Gastroenterology ACG Annual 54 Ambrisentan 54 Clinical Endocrinologists AACE 54 Severe Sepsis 54 CYPHER R Sirolimus Eluting 54 briakinumab 54 Phase 2a Study 54 Solid Tumors 54 STELARA TM 54 Nephrology Annual Meeting 54 SCHWARZ PHARMA 54 Tracleer ® bosentan 54 Tarceva TM 54 Neuromodulation Society 54 Osseointegration 54 Natalizumab 54 AASLD Meeting 54 ABRF 54 PEGylated interferon beta 1a 54 Molecular Biology Organization 54 aclidinium bromide 54 QNEXA ® 54 Phase IIIb study 54 Cardio Thoracic Surgery 54 Phase 1b trial 54 Phase 2a trial 54 Oral Presentation 54 prospective multicentre 54 th Interscience Conference 53 Neuromuscular Diseases 53 Clinical Oncology 53 Endovascular Therapy 53 PEGylated anti 53 Prolongs Survival 53 EMBLEM TM 53 multicentre 53 EchoCRT 53 randomized discontinuation trial 53 Marrow Transplantation 53 Oral Presentations 53 BioPartnering Europe 53 Immunodeficiencies 53 Menopause Society NAMS 53 ARVO 53 Tracleer R 53 Eurofi conference 53 HCV SPRINT 53 Nesiritide 53 Neurology Annual Meeting 53 congress ECCO 53 J Clin Endocrinol Metab 53 Pivotal Trial 53 SWX RO SWX ROG 53 IIIa inhibitor 53 San Antonio Breast Cancer 53 Neurological Surgeons AANS 53 Cimzia certolizumab pegol 53 severe hypercholesterolemia 53 Phase III ALLEGRO 53 multicenter placebo controlled 53 AABB Annual Meeting 53 lucinactant 53 Vimpat lacosamide 53 Removab 53 VEITHsymposium 53 Clinical Chemistry 53 Nordic ACTI 53 Phase 2a clinical 53 GAMMAGARD 53 Pediatric Academic Society 53 AVADO 53 relapsing remitting MS RRMS 53 Investigational Compound 53 histone deacetylase HDAC inhibitor 53 TEMODAL 53 Nexavar sorafenib 53 Hematological 53 Eluting Coronary Stent System 53 AACR IASLC Joint 53 multicentre randomized 53 Tasigna nilotinib 53 eltrombopag 53 glucocorticoid induced osteoporosis 53 ACC.# 53 ISMB 53 ARIXTRA 53 ESOMAR 53 Adenuric R 53 candesartan cilexetil 53 Cachexia 53 Arch Neurol 53 HCV Protease Inhibitor 53 CTAP# Capsules 53 dual endothelin receptor antagonist 53 Annual Interscience Conference 53 Bazedoxifene 53 Prospective Randomized 53 Endovascular Therapy ISET 53 Nephrology CJASN 53 Lung Cancer IASLC 53 EVEREST II 53 Hematological Malignancies 53 thetreatment 53 Val HeFT 53 Pharmacokinetic 53 YONDELIS 53 Adalimumab 53 Long Term Efficacy 53 metastatic castration resistant 53 recurrent GBM 53 catheter occlusion 53 Gynecologic Oncology Group 53 ALN TTR 53 XXIst 53 Receives Orphan Drug Designation 53 Phase III Trial 53 Marrow Transplantation EBMT 53 NSABP B 53 efalizumab 53 Am J Epidemiol 53 Cancer Patients Treated 53 CTRC AACR 53 Endeavor Drug Eluting 53 Breaking Clinical Trials 53 APTIVUS R 53 TXPO 53 Minimally Invasive Spine Surgery 53 Environ Health Perspect 53 Xyrem ® 53 epoetin beta 53 biologic therapy 53 Pulmonary Arterial Hypertension 53 Echocardiography ASE 53 essential thrombocythemia ET 53 Initiates Phase III 53 paliperidone palmitate 53 Randomized Phase 53 American Roentgen Ray 53 Radiation Oncology ASTRO 53 International Neuropsychological Society 53 methotrexate MTX 53 Platelet Inhibition 53 rotigotine transdermal patch 53 Hyperthermic Oncology 53 Nasdaq ALXN 53 Targeted Anticancer Therapies 53 fosbretabulin 53 rivaroxaban Xarelto 53 Increlex R 53 Preclinical Study 53 BoNTA 53 ritonavir boosted 53 abstracts summarizing 53 brivaracetam 53 MEND CABG 53 SUCCEED trial 53 Orphan Medicinal Product 53 liposome injection 53 Complicated Skin 53 Phase IIa 53 IMiDs ® compound 53 Arch Surg 53 Human Brain Mapping 53 BOLDER II 53 Yondelis ® 53 Optical Communication ECOC 53 APPRAISE 53 relapsing multiple sclerosis 53 FDA Oncologic Drugs 53 Endoscopic Surgery 53 Cardiovascular Disease Epidemiology 53 ATACAND 53 Phase 2b Clinical Trial 53 ACOMPLIA R 53 ENDEAVOR III 52 pharmacokinetic PK 52 Plaque Psoriasis 52 Nephrology ASN 52 RE LY trial 52 prospective observational 52 prospective multicenter 52 Cellular Therapy ISCT 52 Firdapse TM amifampridine phosphate 52 Anesthesiologists ASA 52 Human Genetics ASHG 52 REMINYL ® 52 Annual ICAAC 52 Pyridorin 52 Nexavar tablets 52 Surgeons ACS 52 Nasdaq DVAX 52 Golimumab 52 Ocular Pharmacology 52 multicenter phase 52 Epilepsy Society 52 Poster Presentations 52 Phase IIa clinical 52 International Primatological Society 52 Cardiovascular Interventions 52 Celebrex celecoxib 52 Poster Discussion 52 Efficacy Results 52 Acute Ischemic Stroke 52 CUSTOM II 52 Drugs Affecting Lipid 52 clinical pharmacology studies 52 Initiates Enrollment 52 Rivaroxaban 52 Pegasys ® 52 transthyretin TTR mediated amyloidosis 52 Pressure Ulcer Advisory Panel 52 post operative ileus 52 iSBTc 52 guanfacine extended release 52 Ocular Inflammation 52 psoriatic arthritis PsA 52 NAASO 52 Gentium Announces 52 Endocrinology 52 desvenlafaxine succinate 52 Hopital Pitie Salpetriere 52 sipuleucel T 52 Syndrome LEMS 52 CHEST 52 Centre Hospitalier Universitaire Vaudois 52 Telzir 52 Nephrol Dial Transplant 52 Orphan Drug status 52 oral prodrug 52 Human Medicinal Products 52 Microbiology ASM 52 Geochimica et Cosmochimica Acta 52 PROVENGE sipuleucel T 52 Trobalt 52 ProSavin 52 HFSA Annual 52 Gene Therapy ASGT 52 Outpatient Setting 52 Meets Primary Endpoint 52 orphan designation 52 Receives Positive Opinion 52 xanthine oxidase inhibitor 52 Rheumatism EULAR 52 Randomized Double blind 52 Clinical Oncology ASCO Gastrointestinal 52 Medical Research Katholic 52 Rheumatology Annual Meeting 52 Societe Internationale 52 Remote Sensing ASPRS 52 Lambert Eaton Myasthenic 52 Molecular Biology Organization EMBO 52 CYT# potent vascular disrupting 52 EuroIntervention 52 PRECISE 52 Phase Ib study 52 Chronic Heart Failure 52 Institut Jules Bordet 52 #:#-# [031] 52 Plicera 52 Pharmacological Society 52 SNT MC# 52 Phase 1a clinical 52 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 52 GTC recombinant human 52 Physical Therapy PTJ 52 Diabetology 52 FASEB J. 52 Brachytherapy Society 52 ADVANCE PD 52 pan HDAC inhibitor 52 phase IIa clinical 52 ESHO 52 worsening thrombocytopenia 52 evaluating mipomersen 52 GABITRIL 52 Egrifta 52 Metabolic Disorders 52 Patients Treated With 52 rilonacept 52 primary hypercholesterolemia 52 placebo controlled clinical 52 pain palliation 52 liver resection surgeries 52 Sprycel dasatinib 52 Institute Jules Bordet 52 Application MAA 52 MabCampath 52 Glatiramer Acetate 52 PROactive study 52 trials RCTs 52 QVAR ® 52 Severe Asthma 52 Tiotropium 52 Vaccine Adjuvant 52 anti arrhythmic drug 52 somatostatin analog 52 Octreolin 52 CG# [003] 52 Exforge HCT 52 Tolvaptan 52 substudy 52 TRANSFORMS 52 Oncologic Drugs Advisory 52 headache nasopharyngitis 52 metaglidasen 52 containing granisetron 52 Proc Am Soc 52 Forsteo 52 mGluR5 negative 52 colesevelam HCl 52 Orphan Diseases 52 Annual BIO 52 Movement Disorder 52 ASCRS 52 HCV RESPOND 2 52 Cardiol 52 multicenter study 52 BIOCOM Investor Conference 52 icatibant 52 Quinamed 52 Antimicrobial Chemotherapy 52 Antiplatelet 52 Granted Orphan Drug 52 LSE ASM 52 Bucindolol 52 Recurrent Chest Wall 52 Avastin bevacizumab 52 MADIT CRT 52 Stent Thrombosis 52 FDA Endocrinologic 52 FIP Pharmaceutical 52 Nebulized Formoterol 52 Milnacipran 52 multicenter Phase II 52 Refractive Surgery ASCRS 52 SCAI Annual 52 ABSORB 52 Bichat Claude Bernard 52 DASISION 52 recurrent malignant glioma 52 Myeloproliferative Neoplasms 52 Kahalalide F 52 Pneumology 52 neovascular age 52 Rasilez HCT 52 Artificial Organs 52 Respiratory Viral Infections 52 Remote Patient Monitoring 52 Aggressive Reduction 52 MAGE A3 ASCI 52 Clinical Practice Guidelines 52 Raptiva ® 52 NASDAQ CYTK announced 52 ASGCT 52 Arch Intern Med 52 BRIM2 52 anti inflammatory NSAID 52 vismodegib 52 FDA Dermatologic 52 BENICAR 52 Recordati SpA 52 ORENCIA R 52 AA Amyloidosis 52 IASLC 52 adult chronic ITP 52 tasocitinib 52 MERLIN TIMI 52 apremilast 52 Inhalation Solution 51 EMBO J. 51 MAA submission 51 Phase 2b trial 51 Clinical Antipsychotic Trials 51 Nasdaq GNTA 51 Heart Rhythm 51 Liver Meeting 51 AZILECT R 51 Interventional Therapies 51 rALLy trial 51 Wound Healing Society 51 #:# -# [004] 51 vascular disrupting agent 51 Erythropoiesis Stimulating Agents ESAs 51 multicenter 51 BIO InvestorForum 51 Advanced Renal Cell 51 patients undergoing percutaneous 51 Roche MabThera 51 TASKi2 51 BCR ABL inhibitor 51 Inflammatory Arthritis 51 Metabolic Drugs Advisory 51 investigational antiplatelet agent 51 atypical Hemolytic Uremic Syndrome 51 selective modulator 51 Endovascular Valve Edge 51 Phase IIa trial 51 undergoing elective percutaneous 51 HyQ 51 CNTO 51 Atrial Fibrillation Symposium 51 SAEM Annual Meeting 51 Metastatic Melanoma 51 BYETTA ® 51 Pre RELAX AHF 51 NASONEX 51 Relapsing Multiple Sclerosis 51 Bendamustine 51 R lenalidomide 51 NeoRecormon 51 Onrigin 51 mesylate tablets 51 J Am Soc 51 IMPAKT Breast Cancer 51 Thoracic Oncology 51 morphometric vertebral fractures 51 Androxal TM 51 Experimental Biology Annual Meeting 51 Dalbavancin 51 Ocrelizumab 51 OMP designation 51 Inc. Nasdaq BIOD 51 NAVISTAR R 51 relapsing remitting multiple sclerosis 51 levocetirizine 51 DDW 51 pertuzumab 51 Immunology AAAAI 51 efficacy tolerability 51 relapsed refractory multiple myeloma 51 CAMMS# 51 th Annual Interscience 51 Heart Failure 51 chromium supplementation 51 Torisel 51 Molecular Medicine Tri 51 Calcium Acetate 51 Gastrointestinal Oncology 51 Marketing Authorization Application 51 DU #b 51 Midcap Event 51 preclinical efficacy 51 ASTRO Annual Meeting 51 Ramelteon 51 Denufosol 51 TYGACIL 51 ACCOMPLISH 51 Evoltra ® 51 Coronary Revascularization 51 Inc. NASDAQ HEPH 51 ASCO 51 Paroxysmal Nocturnal Hemoglobinuria PNH 51 Bipolar Disorders 51 ASTEROID 51 TAXUS Element Paclitaxel Eluting 51 REACH Registry 51 paroxysmal nocturnal hemoglobinuria PNH 51 Respiratory Care AARC 51 placebo controlled clinical trials 51 sNDA submission 51 TWYNSTA ® 51 FOCIS 51 Phase Ib II 51 Phase Ib clinical 51 ACTEMRA 51 PRNewswire FirstCall Genta Incorporated 51 Phase #/#a 51 AAPOS 51 plus Copegus R 51 Candesartan 51 PRECiSE 51 Gemzar ® 51 Controlled Release 51 ENDO 51 Frovatriptan 51 bardoxolone methyl 51 Refractory Angina 51 Hygiene ASTMH 51 journal Arteriosclerosis Thrombosis 51 HeFH 51 randomized controlled clinical 51 commercialize oritavancin 51 REMICADE ® 51 CALGB 51 Fingolimod 51 Vitrasert R 51 phase IIb 51 Sebivo 51 ACUITY trial 51 Aflibercept 51 SPIRIT FIRST 51 DORIBAX 51 FASLODEX 51 Overactive Bladder 51 valsartan 51 Microplasmin 51 LibiGel ® 51 phase IIa 51 Ophthalmology AAO 51 Phase III psoriasis 51 Nasdaq REGN 51 Benign Prostatic Hyperplasia 51 EGS# 51 Am J Pathol 51 GRNCM1 51 mTOR inhibitor 51 Completes Patient Enrollment 51 sorafenib Nexavar 51 mg administered orally 51 ESPCI 51 HORIZONS AMI 51 phase Ib 51 Treatment Resistant 51 neratinib 51 OTO EXPO 51 diarrhea predominant irritable 51 Clinical Dermatology 51 HuMax EGFr 51 Evaluation WISE 51 Stem Cell Research ISSCR 51 multicenter Phase 51 Pivotal Clinical Trial 51 Ophthalmology ARVO 51 Chemotherapy ICAAC Infectious Diseases 51 kidney urologic 51 CALGB # [002] 51 Hormone Refractory Prostate Cancer 51 coronary stent merged 51 NASDAQ SLXP today 51 Zenvia ™ 51 STRIDE PD 51 CardioFit 51 Investigational Drug 51 Thrombosis 51 SUTENT ® 51 SABER ™ 51 Cardiovascular Therapeutics 51 CUSTOM III 51 Erythropoiesis Stimulating Agents 51 Primary endpoints 51 oral rivaroxaban 51 INCB# [003] 51 Subgroup Analysis 51 adalimumab Humira 51 antiplatelet agent 51 Genital Infection 51 HORIZONS AMI trial 51 Hospital Universitari 51 International Verapamil SR 51 Presents Preclinical 51 TAXUS TM 51 R darbepoetin alfa 51 BCIRG 51 sunitinib Sutent 51 Telmisartan 51 Investigative Dermatology 51 de la Recherche Médicale 51 Phase IIIb 51 Thoraxcenter Erasmus University 51 methylnaltrexone bromide 51 Aclasta 51 Neuropharmacology 51 rivaroxaban 51 Dasatinib 51 Arthroscopy Association 51 Cutaneous T 51 Tracleer r 51 multicenter randomized 51 HIF PH inhibitors 51 PNP inhibitor 51 ILLUMINATE 51 Amgen Nplate 51 Announces Poster Presentations 51 epoetin zeta 51 Annual Meeting 51 UZ Brussel 51 Systemic Lupus Erythematosus 51 Basilea Toctino R 51 ENLIGHT 51 Epidemiological Studies 51 Respiratory Disorders 51 ASH Abstract # 51 Angiox ® 51 Monique MB Breteler 51 NeuroStar TMS Therapy 51 Nephrology ASN Renal 51 abatacept 51 REVLIMID lenalidomide 51 TMS Therapy 51 Vaccine Immunology 51 Reminyl galantamine 51 BRIM3 51 Phase #/#a trial 51 PERSEUS 51 Fifth Decennial International 51 phase IIb trial 51 Metabolic Endocrinology 51 QNEXA 51 Dupuytren Contracture 51 KRN# 51 Cardiac Electrophysiology 51 Silodosin 51 Lodotra 51 Dapagliflozin 51 standard chemotherapy regimen 51 PKC# 51 Endocrine Society 51 GATTEX TM 51 ARBITER 6 51 RRMS patients 51 posaconazole 51 ASM Biodefense 51 ZOLINZA 51 AACR Annual Meeting 50 Chronic Hepatitis B 50 ELSO 50 cardiovascular morbidity 50 Noxafil